Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Adherence-resistance relationships to combination HIV antiretroviral therapy.

Bangsberg DR, Kroetz DL, Deeks SG.

Curr HIV/AIDS Rep. 2007 May;4(2):65-72. Review.

PMID:
17547827
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.

Meresse M, March L, Kouanfack C, Bonono RC, Boyer S, Laborde-Balen G, Aghokeng A, Suzan-Monti M, Delaporte E, Spire B, Carrieri MP, Laurent C; Stratall ANRS 12110/ESTHER Study Group..

HIV Med. 2014 Sep;15(8):478-87. doi: 10.1111/hiv.12140. Epub 2014 Mar 3.

4.

Impact of resistance to antiretroviral therapy in the minority community.

Rodriguez AE, Campo RE, Gathe JC Jr, Kwakwa HA.

AIDS Read. 2004 Oct;14(10 Suppl):S9-11.

PMID:
15497217
5.

Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven.

Lucas GM.

J Antimicrob Chemother. 2005 Apr;55(4):413-6. Epub 2005 Feb 18. Review.

PMID:
15722389
6.

Mechanism of HIV antiretroviral drugs progress toward drug resistance.

Ammaranond P, Sanguansittianan S.

Fundam Clin Pharmacol. 2012 Feb;26(1):146-61. doi: 10.1111/j.1472-8206.2011.01009.x. Epub 2011 Nov 27. Review.

PMID:
22118474
7.

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.

Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, Parkin N, Deeks SG.

AIDS. 2006 Jan 9;20(2):223-31.

PMID:
16511415
8.

Helping the urban poor stay with antiretroviral HIV drug therapy.

Bamberger JD, Unick J, Klein P, Fraser M, Chesney M, Katz MH.

Am J Public Health. 2000 May;90(5):699-701.

9.
10.

Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.

Torti C, Moretti F, Uccelli MC, Tirelli V, Quiros-Roldan E, Gargiulo F, Carosi G.

Med Sci Monit. 2003 Apr;9(4):CS16-9.

PMID:
12709675
11.

Persistence of primary drug resistance among recently HIV-1 infected adults.

Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, Segal MR, Petropoulos CJ, Grant RM.

AIDS. 2004 Aug 20;18(12):1683-9.

PMID:
15280779
12.

Challenges of adherence management in human immunodeficiency virus pharmacotherapy.

Park-Wyllie LY, Phillips EJ.

Can J Clin Pharmacol. 2003 Winter;10(4):189-95. Review.

PMID:
14712324
13.

Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.

Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Stevens WS, Rinke de Wit TF, Schuurman R; PharmAccess African Studies to Evaluate Resistance (PASER)..

Clin Infect Dis. 2012 Jun;54(11):1660-9. doi: 10.1093/cid/cis254. Epub 2012 Apr 3.

PMID:
22474222
14.
15.

Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.

Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN.

J Infect Dis. 2005 Nov 1;192(9):1537-44. Epub 2005 Sep 20.

PMID:
16206068
16.

Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates.

Bangsberg DR, Porco TC, Kagay C, Charlebois ED, Deeks SG, Guzman D, Clark R, Moss A.

J Infect Dis. 2004 Jul 1;190(1):162-5. Epub 2004 Jun 9.

PMID:
15195256
17.

Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.

De Luca A, Hamers RL, Schapiro JM.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S63-9. doi: 10.1093/infdis/jit109. Review.

PMID:
23687291
18.

Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi.

Palombi L, Galluzzo CM, Pirillo MF, Liotta G, Andreotti M, Jere H, Sagno JB, Luhanga R, Mancinelli S, Ceffa S, Amici R, Marazzi MC, Vella S, Giuliano M.

J Antimicrob Chemother. 2014 Mar;69(3):749-52. doi: 10.1093/jac/dkt408. Epub 2013 Oct 17.

PMID:
24135952
19.

Antiretroviral medication adherence and the development of class-specific antiretroviral resistance.

Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR.

AIDS. 2009 Jun 1;23(9):1035-46. doi: 10.1097/QAD.0b013e32832ba8ec. Review.

20.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125

Supplemental Content

Support Center